Department of Dermatology, Federation of National Public Service Personnel Mutual Aid Associations, Hamanomachi Hospital, Fukuoka, Japan; Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Department of Environmental Medicine and Infectious Disease, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
J Dermatol Sci. 2019 Aug;95(2):70-75. doi: 10.1016/j.jdermsci.2019.07.005. Epub 2019 Jul 24.
We sometimes encounter difficulties in assessing the severity of pediatric atopic dermatitis (AD) using currently available biomarkers such as thymus and activation-regulated chemokine (TARC) due to the higher baseline values in non-AD children. Recent case control studies have indicated the usefulness of squamous cell carcinoma antigens (SCCAs) in pediatric and adult AD. Notably, SCCAs are induced by IL-4 and IL-13, vital Th2 cytokines that play important roles in AD etiology.
Relatively low prevalence and mild disease severity of pediatric AD are observed in our Ishigaki cohort presumably due to the moisturising subtropical climate, which could conversely mean possible higher allergic potential of non-AD subjects towards AD. Thus, the purpose of this study was to further investigate the feasibility of using SCCAs together with TARC and periostin as biomarkers for pediatric AD even in the Ishigaki cohort.
We enrolled 1459 nursery school children and identified 96 as having AD through 2009-2011. As statistical analyses, we performed Student's t-test, correlation analysis, and receiver and operating characteristic (ROC) analysis.
Serum SCCA1, SCCA2, periostin and TARC levels were all significantly increased in AD compared with those in non-AD, but only serum SCCA2 showed a significant increase in AD when assessed in each age group or in subgroup analysis. Among the biomarkers tested, serum SCCA2 also showed the best correlations with clinical AD severity and TARC and showed the best diagnosability for AD in ROC analysis.
SCCA2 is a potent biomarker for pediatric AD in the Ishigaki cohort.
由于非特应性皮炎儿童的基础值较高，我们在使用目前可用的生物标志物（如胸腺激活调节趋化因子[TARC]）评估小儿特应性皮炎（AD）的严重程度时，有时会遇到困难。最近的病例对照研究表明鳞状细胞癌抗原（SCCA）在儿科和成人 AD 中的有用性。值得注意的是，SCCAs 是由白细胞介素 4（IL-4）和白细胞介素 13（IL-13）诱导的，这两种细胞因子是重要的 Th2 细胞因子，在 AD 的发病机制中发挥重要作用。
我们在石垣队列中观察到小儿 AD 的患病率相对较低且疾病严重程度较轻，这可能是由于湿润的亚热带气候所致，这反过来可能意味着非 AD 受试者对 AD 可能具有更高的过敏潜力。因此，本研究的目的是进一步研究使用 SCCA 与 TARC 和骨桥蛋白作为生物标志物在石垣队列中诊断小儿 AD 的可行性。
我们招募了 1459 名幼儿园儿童，并通过 2009-2011 年确定了 96 名 AD 儿童。作为统计分析，我们进行了学生 t 检验、相关性分析和接收器和操作特征（ROC）分析。
与非 AD 相比，AD 儿童的血清 SCCA1、SCCA2、骨桥蛋白和 TARC 水平均显著升高，但仅 SCCA2 血清水平在每个年龄组或亚组分析中均显著升高。在测试的生物标志物中，SCCA2 与临床 AD 严重程度和 TARC 的相关性也最好，ROC 分析显示其对 AD 的诊断能力也最好。
SCCA2 是石垣队列中小儿 AD 的有效生物标志物。
